Physician profile
Steven Phillip Ellis
NPI 1821431123
$10,470.78
in general payments reported to CMS, 2019-2025
62 companies · $977 in 2025
The $977 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $770 · 2021: $999 · 2022: $2,594 · 2023: $1,918 · 2024: $2,597 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,598 · Travel and Lodging: $762 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,598.45 |
| Travel and Lodging | $762.01 |
| Education | $130.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,668.29 | 2019-2025 | |
| Livanova USA, INC. | $976.98 | 2019-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Medtronic, INC. | $599.51 | 2022-2023 | Percept Pc Brainsense |
| Jazz Pharmaceuticals INC. | $534.46 | 2020-2025 | Epidiolex, Xywav |
| Genzyme Corporation | $461.75 | 2019-2025 | |
| Argenx US, INC. | $404.00 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $402.77 | 2020-2025 | Mavenclad |
| Ucb, INC. | $342.38 | 2019-2024 | Briviact, Zilbrysq, Rystiggo |
| Pfizer INC. | $286.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $268.17 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $243.68 | 2019-2023 | Nuplazid |
| Amneal Pharmaceuticals LLC | $235.95 | 2019-2023 | Rytary |
| Biohaven Pharmaceutical Holding Company Ltd. | $233.96 | 2022 | |
| Neurocrine Biosciences, INC. | $220.48 | 2019-2025 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $206.42 | 2020-2021 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.